Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preventive Anticoagulation with Dalteparin in Metastatic Pancreatic Cancer
NCT00662688Phase 3Terminated
- Sponsor
- GERCOR
- Start
- Oct 2007
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dalteparin in thromboembolism (2 arms), sponsored by GERCOR. Primary endpoint: Number of thromboembolic events. Started Oct 2007; status: terminated.
02
Drugs
dalteparin
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT00662688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00662688.